Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High – Time to Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.43 and last traded at $29.94, with a volume of 236913 shares changing hands. The stock had previously closed at $28.75.

Analyst Ratings Changes

Several analysts recently weighed in on ELVN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Enliven Therapeutics Trading Up 3.5%

The firm has a market capitalization of $1.77 billion, a P/E ratio of -16.17 and a beta of 0.33. The company has a 50-day moving average of $24.53 and a 200-day moving average of $21.68.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the completion of the sale, the insider directly owned 740,188 shares in the company, valued at approximately $21,495,059.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares in the company, valued at $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 233,843 shares of company stock valued at $6,145,489. 25.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $180,000. Invesco Ltd. lifted its position in shares of Enliven Therapeutics by 7.0% during the 4th quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock valued at $381,000 after acquiring an additional 1,624 shares during the period. XTX Topco Ltd boosted its stake in Enliven Therapeutics by 472.6% during the fourth quarter. XTX Topco Ltd now owns 60,702 shares of the company’s stock worth $935,000 after acquiring an additional 50,101 shares in the last quarter. Vestal Point Capital LP boosted its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares in the last quarter. Finally, Virtus Investment Advisers LLC grew its holdings in Enliven Therapeutics by 172.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company’s stock worth $243,000 after purchasing an additional 9,991 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.